EMD Millipore Receives Recertification of GMP Compliance for Biodevelopment Centre - - BioPharm International

ADVERTISEMENT

EMD Millipore Receives Recertification of GMP Compliance for Biodevelopment Centre



EMD Millipore reported that its Biodevelopment Centre in Martillac, France, has been recertified by the French National Agency for Medicines and Health Products Safety, the competent authority of France. The certification confirms the 3440 m2 facility complies with the principles of GMP for active substances. The audit included a thorough review of quality systems, supplier management, control of raw materials, documentation, calibration and validation. Prior certification consisted only of stainless steel equipment, while this recertification included complete single-use upstream and downstream suites, as well as a 2 x 1250 L stainless steel suite.

EMD Millipore's Provantage biodevelopment and clinical supply services are delivered at the Martillac, France facility. This approach for biologics manufacturing incorporates technologies in upstream, downstream and single-use systems. This Provantage offering includes process development and GMP drug substance for pre-clinical to Phase II and is available to a global customer base.

Source: EMD Millipore
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines

Click here